Teleflex (NYSE:TFX) Given a $130.00 Price Target by Royal Bank Of Canada Analysts

Teleflex (NYSE:TFX) has been assigned a $130.00 price target by equities research analysts at Royal Bank Of Canada in a research report issued on Tuesday, Marketbeat Ratings reports. The brokerage presently has a “sector perform” rating on the medical technology company’s stock. Royal Bank Of Canada’s price target would suggest a potential upside of 14.71% from the stock’s current price.

A number of other equities research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Teleflex from a “buy” rating to a “hold” rating in a report on Sunday, June 29th. Morgan Stanley dropped their price target on shares of Teleflex from $191.00 to $173.00 and set an “overweight” rating for the company in a research note on Monday, May 5th. Mizuho set a $155.00 price target on shares of Teleflex in a research report on Wednesday, April 16th. Wells Fargo & Company decreased their price objective on Teleflex from $146.00 to $137.00 and set an “equal weight” rating on the stock in a report on Friday, May 2nd. Finally, Truist Financial cut their target price on Teleflex from $140.00 to $137.00 and set a “hold” rating for the company in a research note on Monday, May 5th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $159.63.

Teleflex Stock Down 0.1%

TFX opened at $113.33 on Tuesday. The company has a market cap of $5.01 billion, a PE ratio of 35.75, a price-to-earnings-growth ratio of 1.78 and a beta of 1.08. Teleflex has a twelve month low of $112.32 and a twelve month high of $249.91. The company has a 50-day moving average price of $121.24 and a 200 day moving average price of $142.41. The company has a quick ratio of 1.32, a current ratio of 2.28 and a debt-to-equity ratio of 0.44.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, topping the consensus estimate of $2.88 by $0.03. The firm had revenue of $700.67 million during the quarter, compared to analysts’ expectations of $699.37 million. Teleflex had a return on equity of 14.73% and a net margin of 4.96%. The firm’s revenue for the quarter was down 5.0% on a year-over-year basis. During the same period in the previous year, the business earned $3.21 earnings per share. Sell-side analysts expect that Teleflex will post 13.98 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Teleflex

Institutional investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new position in shares of Teleflex during the fourth quarter worth about $100,328,000. Dimensional Fund Advisors LP boosted its position in shares of Teleflex by 69.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 867,864 shares of the medical technology company’s stock valued at $119,927,000 after purchasing an additional 355,720 shares during the period. Invesco Ltd. grew its stake in Teleflex by 48.1% during the 4th quarter. Invesco Ltd. now owns 1,068,593 shares of the medical technology company’s stock worth $190,188,000 after buying an additional 347,003 shares during the last quarter. Diamond Hill Capital Management Inc. increased its position in Teleflex by 122.8% during the first quarter. Diamond Hill Capital Management Inc. now owns 584,586 shares of the medical technology company’s stock worth $80,784,000 after buying an additional 322,222 shares during the period. Finally, Invenomic Capital Management LP increased its position in Teleflex by 1,400.1% during the first quarter. Invenomic Capital Management LP now owns 344,732 shares of the medical technology company’s stock worth $47,639,000 after buying an additional 321,751 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.